ID   CUTO-28-CR
AC   CVCL_C8T8
SY   CUTO28CR
DR   Wikidata; Q123030992
RX   DOI=10.1158/1535-7163.TARG-21-P076;
CC   Selected for resistance to: ChEBI; CHEBI_64310; Crizotinib (Xalkori).
CC   Sequence variation: Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:12012; TPM3; Name(s)=TPM3-ROS1 (DOI=10.1158/1535-7163.TARG-21-P076).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C8T2 ! CUTO-28
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 19-12-24; Version: 3
//
RX   DOI=10.1158/1535-7163.TARG-21-P076;
RA   Tyler L.C., Le A.T., Nijmeh H., Bao L.-M., Turner K.,
RA   Christianson J., Doebele R.C.;
RT   "Novel mechanisms of acquired TKI resistance in ROS1+ NSCLC.";
RL   Mol. Cancer Ther. 20 Suppl. 12:P076-P076(2021).
//